Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04575610 · ClinicalTrials.gov registry record · Phase 2
IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04575610 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants.
The verdict
NCT04575610, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19.
Interventions
- DRUG Placebo
- DRUG PF-06650833
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-11-27 |
| Est. Completion | 2021-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04575610
The ClinicalTrials.gov registry entry for NCT04575610 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04575610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04575610 about?
NCT04575610 is a clinical study titled "IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)". The purpose of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19.
What is the current status of trial NCT04575610?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-11-27. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT04575610?
The interventions under investigation include: Placebo (DRUG), PF-06650833 (DRUG).
Who is sponsoring clinical trial NCT04575610?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.